Literature DB >> 18726700

Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II.

Florian Stockhammer1, Andreas von Deimling, Michael Synowitz, Cristiane Blechschmidt, Frank K H van Landeghem.   

Abstract

Objective Oligodendroglial tumors with a loss of heterozygosity of 1p (LOH1p) appear to have a better prognosis than oligodendrogliomas without LOH. Previously, we reported glucose uptake in low-grade oligodendroglial tumors to be related to LOH 1p status. Here, we performed an immunohistochemical study of the common glucose transporters (GLUT) in relation to LOH1p. Material and methods We examined 17 oligodendrogliomas (O II, 11 with LOH1p), 16 oligoastrocytomas (OA II, 5 with LOH1p) and 7 astrocytomas (A II, none with LOH1p). Confocal microscopy was performed for p53, GLUT-1, -3 and -12. Immunoreaction was rated semiquantitatively by percentage of positive cells and staining intensity on immunohistological stainings. Results Confocal microscopy depicted immunoreaction for GLUT-1, -3 and -12 in the cytoplasm of the tumor cells. Oligodendrogliomas revealed a lower immunoreactivity for GLUT-1 than oligoastrocytomas and astrocytomas (P = 0.0263). No differences in immunoreactivity were found for GLUT-3 and GLUT-12. GLUT-1 expression in tumors with LOH 1p was significantly lower than in tumors with wild type 1p status (P = 0.0017). GLUT-3 and GLUT-12 immunoreactivity was not correlated with LOH 1p. Conclusion Expression of GLUT-1 is significantly reduced in low-grade oligodendroglial tumors harboring LOH 1p. Further studies should address the functional role of GLUT-1 in regard to chemosensitivity of oligodendrogliomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726700     DOI: 10.1007/s10735-008-9191-0

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  41 in total

1.  Identification of a novel glucose transporter-like protein-GLUT-12.

Authors:  Suzanne Rogers; Maria L Macheda; Susan E Docherty; Maynard D Carty; Michael A Henderson; Walter C Soeller; E Michael Gibbs; David E James; James D Best
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-03       Impact factor: 4.310

Review 2.  Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies.

Authors:  L Bubendorf; A Nocito; H Moch; G Sauter
Journal:  J Pathol       Date:  2001-09       Impact factor: 7.996

3.  Expression and localization of GLUT1 and GLUT12 in prostate carcinoma.

Authors:  Jenalle D Chandler; Elizabeth D Williams; John L Slavin; James D Best; Suzanne Rogers
Journal:  Cancer       Date:  2003-04-15       Impact factor: 6.860

4.  Neurons and microvessels express the brain glucose transporter protein GLUT3.

Authors:  D Z Gerhart; M A Broderius; N D Borson; L R Drewes
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

5.  Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas.

Authors:  Florian Stockhammer; Ulrich-Wilhelm Thomale; Michail Plotkin; Christian Hartmann; Andreas Von Deimling
Journal:  J Neurosurg       Date:  2007-04       Impact factor: 5.115

6.  Differential expression of GLUT12 in breast cancer and normal breast tissue.

Authors:  Suzanne Rogers; Susan E Docherty; John L Slavin; Michael A Henderson; James D Best
Journal:  Cancer Lett       Date:  2003-04-25       Impact factor: 8.679

7.  Distribution of the glucose transporters in human brain tumors.

Authors:  T Nishioka; Y Oda; Y Seino; T Yamamoto; N Inagaki; H Yano; H Imura; R Shigemoto; H Kikuchi
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

8.  Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death.

Authors:  Roy Blum; Jasmine Jacob-Hirsch; Ninette Amariglio; Gideon Rechavi; Yoel Kloog
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

9.  The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression.

Authors:  Fabiana Schwartzenberg-Bar-Yoseph; Michal Armoni; Eddy Karnieli
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

10.  Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells.

Authors:  S B Wharton; E Maltby; D A Jellinek; D Levy; N Atkey; S Hibberd; D Crimmins; K Stoeber; G H Williams
Journal:  Acta Neuropathol       Date:  2006-12-09       Impact factor: 17.088

View more
  3 in total

1.  GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling.

Authors:  Mark A White; Efrosini Tsouko; Chenchu Lin; Kimal Rajapakshe; Jeffrey M Spencer; Sandi R Wilkenfeld; Sheiva S Vakili; Thomas L Pulliam; Dominik Awad; Fotis Nikolos; Rajasekhara Reddy Katreddy; Benny Abraham Kaipparettu; Arun Sreekumar; Xiaoliu Zhang; Edwin Cheung; Cristian Coarfa; Daniel E Frigo
Journal:  Endocr Relat Cancer       Date:  2018-02-05       Impact factor: 5.678

2.  Hypoxia-inducible factor-1-regulated protein expression and oligodendroglioma patient outcome: comparison with established biomarkers and preoperative UCSF low-grade scoring system.

Authors:  Shirley Abraham; Nan Hu; Randy Jensen
Journal:  J Neurooncol       Date:  2012-03-06       Impact factor: 4.130

3.  Could GLUT12 be a Potential Therapeutic Target in Cancer Treatment? A Preliminary Report.

Authors:  Jonai Pujol-Gimenez; Fátima Pérez de Heredia; Miguel Angel Idoate; Rachel Airley; María Pilar Lostao; Andrew Robert Evans
Journal:  J Cancer       Date:  2015-01-05       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.